Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Respimat

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    85 result(s) found for: Respimat. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2019-002256-16 Sponsor Protocol Number: 19-01SPIOMI Start Date*: 2020-01-28
    Sponsor Name:Fraunhofer Society
    Full Title: Acute and two-week effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on cardiac function, the autonomic nervous system and small airway function in hyperinflated COPD subjects
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015713-51 Sponsor Protocol Number: 205.452 Start Date*: 2010-06-09
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG, Medical Affairs Germany
    Full Title: A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FI (Completed) LV (Completed) HU (Completed) NO (Completed) LT (Completed) SK (Completed) SE (Completed) ES (Completed) NL (Completed) DK (Completed) PT (Completed) GR (Completed) AT (Completed) IT (Completed) IE (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004829-29 Sponsor Protocol Number: 1222.6 Start Date*: Information not available in EudraCT
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy (bronchodilation) and safety of 4 weeks of once daily treatment of orally inhaled BI 1744 CL (2 µg, 5 µg, 1...
    Medical condition: Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-002694-52 Sponsor Protocol Number: 1012.56 Start Date*: 2007-01-05
    Sponsor Name:Boehringer Ingelheim France
    Full Title: A comparison of ipratropium bromide/salbutamol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the Respimat in a 12-week, double-blind, safety...
    Medical condition: Adults with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-018006-21 Sponsor Protocol Number: 205.420 Start Date*: 2010-06-10
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase II, randomised, double- blind, placebo controlled, cross-over efficacy and safety comparison of tiotropium 5 μg administered once daily (in the evening) and tiotropium 2.5 μg administered t...
    Medical condition: moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) EE (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001719-21 Sponsor Protocol Number: 1237-0095 Start Date*: 2019-12-23
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomized, double blind, placebo-controlled, multi-center, parallel group study to compare the efficacy of inhaled tiotropium + olodaterol, fixed dose combination (5μg/5μg) vs. placebo delivered...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000529-19 Sponsor Protocol Number: TUD-TRIBOR-072 Start Date*: 2020-12-14
    Sponsor Name:Technische Universität Dresden
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSS-OVER STUDY FOR EVALUATION OF THE EFFICIENCY AND SAFETY OF TIOTROPIUM INHALATION SOLUTION (5 µG) VIA RESPIMAT® INHALER once a day for 24 weeks fo...
    Medical condition: Children (6-12 years old) with bronchopulmonary dysplasia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006475 Bronchopulmonary dysplasia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001801-29 Sponsor Protocol Number: 1298.3 Start Date*: 2011-10-26
    Sponsor Name:Boehringer Ingelheim
    Full Title: A single dose, randomised, placebo-controlled, double-blind, 5-way crossover (employing an incomplete block design), efficacy (including 24-h pulmonary function tests) and safety comparison of Ti...
    Medical condition: Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022458-18 Sponsor Protocol Number: 205.425 Start Date*: 2011-05-23
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase II randomised, double-blind, placebo-controlled incomplete cross-over trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25 μg...
    Medical condition: Moderate persistent asthma in children 6 to 11 years old
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003555 Asthma bronchial LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) LT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-018471-26 Sponsor Protocol Number: 205.380 Start Date*: 2010-10-12
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase II randomised, double-blind, placebo controlled, cross-over efficacy and safety comparison of three doses of tiotropium inhalation solution delivered via Respimat® inhaler (1.25, 2.5 and 5....
    Medical condition: moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019802-17 Sponsor Protocol Number: 205.438 Start Date*: 2010-09-13
    Sponsor Name:Boehringer Ingelheim France
    Full Title: A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 μg administered once daily via the Respimat® device in pati...
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) FR (Completed) SK (Completed) DE (Completed) GB (Completed) BE (Completed) CZ (Completed) IT (Completed) AT (Completed) IE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000650-79 Sponsor Protocol Number: 1205.4 Start Date*: 2005-09-05
    Sponsor Name:Boehringer Ingelheim Coordination Centre Belgium
    Full Title: A Randomized, Multiple-dose, Double-Blind, Placebo- and Active-Controlled, Parallel Group Efficacy and Safety Study to determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat Inhaler in...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017745-55 Sponsor Protocol Number: 205.424 Start Date*: 2010-05-03
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase II randomised, double-blind, placebo-controlled, incomplete crossover trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25μg,...
    Medical condition: Moderate persistent asthma in adolescents (12 to 17 years old)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003555 Asthma bronchial LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) SI (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2009-016251-21 Sponsor Protocol Number: 205.458 Start Date*: 2010-10-29
    Sponsor Name:Boehringer Ingelheim
    Full Title: Pharmacokinetics and dose-ranging of tiotropium inhalation solution delivered from the Respimat inhaler in patients with Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-001615-13 Sponsor Protocol Number: 1 Start Date*: 2015-07-31
    Sponsor Name:Imperial College London
    Full Title: TARGETING OF THE SMALL AIRWAYS IN PATIENTS WITH COPD: AIRWAY EFFECTS OF TIOTROPIUM -Respimat vs. Handihaler
    Medical condition: Chronic Obstructive Pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021093-11 Sponsor Protocol Number: 205.444 Start Date*: 2010-11-13
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily ) del...
    Medical condition: moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) ES (Completed) SK (Completed) IT (Prematurely Ended) DE (Completed) NO (Ongoing) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004710-42 Sponsor Protocol Number: 1237.20 Start Date*: 2012-04-23
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over trial to characterise the 24-hour lung function profiles of tiotropium + olodaterol fixed dose combination...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) DK (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-005317-23 Sponsor Protocol Number: 2013RC06 Start Date*: 2015-11-16
    Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside
    Full Title: Effects of ultra-long acting bronchodilator therapy assessed by impulse oscillometry in smoking asthmatics taking inhaled corticosteroids
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005087-26 Sponsor Protocol Number: 1237.4 Start Date*: 2008-06-25
    Sponsor Name:Boehringer Ingelheim GmbH & Co. KG
    Full Title: Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination with 5µg ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000532-22 Sponsor Protocol Number: PT001102 Start Date*: 2020-02-28
    Sponsor Name:Pearl Therapeutics Inc. [...]
    1. Pearl Therapeutics Inc.
    2. Pearl Therapeutics Inc.
    3. Pearl Therapeutics Inc.
    Full Title: A Randomized, Double-Blind, Parallel Group, Multi-Center 24 Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persis...
    Medical condition: Subjects With Persistent Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 17:15:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA